Serina Therapeutics (FRA:2BO) OCF Margin %: 0.00% (As of Mar. 2026)


FRA:2BO Serina Therapeutics Inc FRA:2BO
19 GF Score
Price €1.48
! 1 Warning Sign
View Full Analysis

What is Serina Therapeutics OCF Margin %?

Serina Therapeutics FRA:2BO +8.03% 19 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:2BO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 957 Biotechnology companies, Serina Therapeutics ranks worse than 104493.1% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Serina Therapeutics's Cash Flow from Operations for the three months ended in Mar. 2026 was €-3.95 Mil. Serina Therapeutics's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Serina Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Serina Therapeutics's current OCF Yield % is -61.60%.

The historical rank and industry rank for Serina Therapeutics's OCF Margin % or its related term are showing as below:


During the past 5 years, the highest OCF Margin % of Serina Therapeutics was -74.07%. The lowest was -415.20%. And the median was -82.53%.

FRA:2BO's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Serina Therapeutics OCF Margin % Related Terms

Serina Therapeutics OCF Margin % Historical Data

* Premium members only.

The historical data trend for Serina Therapeutics's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Serina Therapeutics OCF Margin % Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
-74.05 -415.25 -82.52 0.00 0.00

Serina Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2BO
19GF Score
Serina Therapeutics Inc FRA:2BO
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Serina Therapeutics OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Serina Therapeutics's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-15.334/0
= %

Serina Therapeutics's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.951/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Serina Therapeutics (FRA:2BO) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Serina Therapeutics and its competitors. According to the industry distribution chart, Serina Therapeutics ranks #999999 out of 957 companies in the Biotechnology industry.
Is Serina Therapeutics' OCF Margin % too high?
Serina Therapeutics' current OCF Margin % is 0.00%. Based on the distribution chart, Serina Therapeutics ranks #999999 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Serina Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' OCF Margin % compare to NRSN and IGC?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #999999 out of 957 companies for OCF Margin %. This places Serina Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Serina Therapeutics and its competitors. Serina Therapeutics's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (FRA:2BO) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Serina Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Serina Therapeutics (FRA:2BO), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Serina Therapeutics Business Description

Other Exchanges SER:USA
Address 601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
19GF Score

Get the complete analysis for FRA:2BO

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.48
Price